It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%," Merck said in a news release. "7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo treated patients (53,377). Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo."
originally posted by: MaplePatriot
Ivermectin and HCQ in varying different protocols from multiple different groups of doctors all across the world has shown that it works, and it works well.
You can't patent those drugs though, so big pharma cannot make billions in taxpayer money for them.
originally posted by: LSU2018
originally posted by: MaplePatriot
Ivermectin and HCQ in varying different protocols from multiple different groups of doctors all across the world has shown that it works, and it works well.
You can't patent those drugs though, so big pharma cannot make billions in taxpayer money for them.
More importantly, Donald Trump made the suggestion of treating coronvirus with that medicine, so democrats fcked the entire population in order to gain power.
originally posted by: Salander
So far my healthy immune system has protected me. Vitamin D and Zinc and sunshine works for me.
I'm going to pass on any products from Pharma to 'protect' me from a virus with a 99% survival rate.
originally posted by: MDDoxs
LOL!
So y'all are okay with this experimental drug?
Is it time for me to switch sides of the argument to point all your hypocrisy. Hahaha
Safety controversy
In April 2020, Rick Bright, who was removed as head of the Biomedical Advanced Research and Development Authority (BARDA) before the approval of the drug, submitted a whistleblower complaint asserting that Ridgeback pressured BARDA to provide funding to manufacture EIDD-2801 despite Bright's concerns that similar drugs in its class have mutagenic properties.[4]
A previous company, Pharmasset, that had investigated the drug's active ingredient had abandoned it over similar concerns.[5] These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020. Also at this time, DRIVE and Ridgeback Biotherapeutics stated they planned future safety studies in animals.[6]